Lead Product Renevia is Being Developed for Several Dermatological Applications;

Report Available Here: http://www.lifescicapital.com/equity-research/biotime/

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioTime Inc. (NYSE: BTX), a clinical-stage biotechnology company focused on regenerative medicine. The Company is developing technologies that utilize stem cells, biomaterials, lab-generated cells and tissues, and biologics to treat various conditions and diseases.

BioTime’s lead asset is Renevia, an adipose tissue replacement device being developed for use in various aesthetic dermatological applications. The Company will initially pursue approval in the EU for the treatment of facial HIV-related lipoatrophy (HRLA), a disorder characterized by fat loss in HIV infected patients related to the use of antiretroviral therapies (ART). Renevia is an implantable matrix that delivers autologous adipose tissue-derived cells to restore texture while promoting soft tissue regeneration over the long term. BioTime is currently conducting a pivotal clinical trial with Renevia for the treatment of facial HRLA, and expects top-line data in the second quarter of 2017.

BioTime is also pursuing the development of OpRegen, a proprietary injection of human embryonic stem cell (hESC) derived retinal pigment epithelium (RPE) cells for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Dry AMD is characterized by late-onset degeneration of RPE and photoreceptor cells in the macula of eye. OpRegen is an allogeneic, or off-the-shelf therapy that aims to integrate hESC-RPE cells into the subretinal space to replace atrophied RPE cells and restore visual function in AMD patients. OpRegen has been granted Fast Track designation by the FDA, which allows for more frequent meetings with the agency regarding development plan and trial design, eligibility for accelerated approval and priority review, and rolling NDA submission. BioTime is currently conducting a Phase I/II dose-escalation study with OpRegen for the treatment of dry AMD with GA, and expects to report novel data in the first half of 2017.

In a 47 page Initiation Report, LifeSci Capital describes the Company’s treatments for HRLA and AMD, how these products are differentiated from other therapies, and the market opportunities for each indication, as well as other potential applications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioTime as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 453854

IRVINE, CA / ACCESSWIRE / January 30, 2017 / PRO-DEX, INC. (NasdaqCM: PDEX) today announced the sale of its Oregon Micro Systems (“OMS”) division, effective on January 27, 2017, located in Beaverton, Oregon, to OMS Motion, Inc., a corporation newly formed by the division’s long time general manager, Mr. Phil Brown. The OMS division designs and manufactures embedded multi-axis motion controllers, which are sold to distributors or original equipment manufacturers in the automation and research industries.

“The sale of our OMS division will allow us to invest in our research and development efforts of our medical device product portfolio,” said Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer. “We are pleased that this sale was consummated so quickly, in part due to the knowledge that Phil has regarding the business and its prospects. We wish Phil and OMS Motion, Inc. continued success in the future, and thank Phil for his many years of service and leadership.”

The aggregate purchase price for the OMS asset sale was $640,000, subject to adjustment based upon the value of the OMS receivables at the date of close.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial, and dental markets. Its Fineline Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex’s products are found in hospitals, dental offices, and medical engineering labs around the world.

Pro-Dex also provides quality and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services Division. For more information, visit the Company’s website at www.pro-dex.com.

Statements herein concerning the Company’s plans, growth, and strategies may include “forward-looking statements” within the context of the federal securities laws. Statements regarding the Company’s future events, developments, and future performance, as well as management’s expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

Contact:

Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

SOURCE: Pro-Dex, Inc.

ReleaseID: 453842

VANCOUVER, BC / ACCESSWIRE / January 30, 2017 / Opawica Explorations Inc. (TSX-V: OPW) (OTC PINK: OPWEF) (the “Company” / “Opawica”) announces that, further to the Company’s news release of October 27, 2016 that announced the initialization of drill mobilization in November 2016, a delay in obtaining access permits has required the Company to amend mobilization arrangements with the drill contractor. Drilling at the Company’s 100% owned Bazooka Property will now commence in mid February 2017.

The Company has also obtained a three month extension on its Option to acquire 100% interest, subject to a 3% gross metal royalty, of the Bazooka West property from Globex Mining Enterprises Inc. (TSX: GMX) that was first announced on August 2, 2016. The final option payment of $30,000 and 500,000 common shares of the Company has been extended to April 30, 2017, for consideration of $5,000 and 250,000 common shares of the Company payable upon receipt of TSX Venture Exchange acceptance of the extension.

The gold mineralization on the Company’s 100% owned Bazooka property, where past drilling has intersected world class gold intercepts, appears to be the extension of the mineralized zones and gold resources known to exist on the western end on the Yorbeau Resources Inc. (“Yorbeau”) Rouyn property. The Yorbeau property has been optioned by Kinross Gold Corporation (“Kinross”), whereby Kinross has the option to acquire a 100% interest in Yorbeau’s Rouyn property for consideration that includes exploration expenditures of C$12 million; cash payments of USD $25,000,000, plus 2% of the prevailing gold price multiplied by the number of ounces of gold in measured, indicated and inferred resources identified in a resource estimate, yet to be completed; as well as other considerations (see Yorbeau press release dated October 25, 2016).

Opawica is mobilizing a drill program that is designed to test the depth extension of the mineralized zone of the underground workings. In 1951-52, Eldona Gold Mines Ltd. sank a shaft to a depth of 125 metres, and at the depth of 114 metres, 634 metres of drifts were developed and the company had reached the fold nose feature of the Cadillac Larder Lake Break (“CLLB”). Four mineralized gold zones were outlined as follows: “Average of back panel samples grading 0.31 oz over 15.0 feet, average of back panel samples grading 0.55 oz over 3.5 feet by 69 feet long, average of back panel samples grading 0.06 oz over 5.3 feet by 60 feet long and channel samples grading 0.21 oz (over a drift section of 10 feet)” (extract from NI 43-101 technical report dated March 20, 2016 filed by the Company on www.sedar.com on April 28, 2016). The Opawica drill program of up to three holes, totalling 1,500 metres, is designed to reach the depth extension of the underground mineralized zone at the depth from 200 to 400 metres.

Significant gold mineralization has been established on the Bazooka property from near surface to approximately 250 metres vertical depth from past drilling by previous owners such as Siscoe (1944) interval of 5.79 metres of 77.18 g/t Au (true width unknown); with more recent drill intercepts ranging from narrow and intermittent anomalous gold values up to Soquem (1981) interval of 7.50 metres of 25.77 g/t Au; Lake Shore Gold Corp. (2003) intercept of 1.25 metres of 94.11 g/t Au; and RT Minerals Corp. values of up to 17 metres of core length at 7.86 g/t Au, including 7.20 metres interval of 16.77 g/t Au (RT Minerals Corp. June 21, 2011 press release). These recent intervals are estimated at approximately 85% to 93% true widths. This gold mineralization is known to exist within 50 metres on strike to the gold mineralization on the Yorbeau property and for a current strike length on Opawica’s Bazooka property and optioned Bazooka West property for approximately seven kilometres.

Mr. Yvan Bussieres, P.Eng., is the Qualified Person who has prepared or supervised the preparation of the information that forms the basis for the scientific and technical disclosure in this news release.

FOR FURTHER INFORMATION CONTACT:

Fred Kiernicki
President and Chief Executive Officer
Opawica Explorations Inc.
Telephone: 604-681-3170
Fax: 604-681-3552

Neither the TSX Venture Exchange nor its Regulation Service Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Statements

Certain statements in this press release relating to the Company’s exploration activities, project expenditures and business plans are approximate and are “forward-looking statements” within the meaning of securities legislation. The Company does not intend, and does not assume any obligation, to update these forward-looking statements. These forward-looking statements represent management’s best judgment based on current facts and assumptions that management considers reasonable, including that operating and capital plans will not be disrupted by issues such as adverse market conditions, mechanical failure, unavailability of parts, labor disturbances, interruption in transportation or utilities, or adverse weather conditions, that there are no material unanticipated variations in budgeted costs, that contractors will complete projects according to schedule, and that actual mineralization on properties may not achieve any category of resource(s). The Company makes no representation that reasonable business people in possession of the same information would reach the same conclusions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In particular, fluctuations in the price of gold, equity markets or in currency markets could prevent the Company from achieving its targets. Readers should not place undue reliance on forward-looking statements. There is no guarantee that drill results reported in this news release or future releases will lead to the identification of a deposit that can be mined economically, and further work is required to identify resources and reserves. We seek safe harbour.

SOURCE: Opawica Explorations Inc.

ReleaseID: 453850

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether DaVita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On January 6, 2017, the Wall Street Journal reported that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.

On this news, DaVita stock fell $2.41, or 3.66%, to close at $63.38 on January 9, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 453848

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Levi & Korsinsky announces it has commenced an investigation of Cabot Microelectronics Corporation (NASDAQ: CCMP) concerning possible breaches of Delaware law by the board of directors of the company. To obtain additional information about the investigation, go to: http://zlk.9nl.com/cabot-microelectronics-ccmp, or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453849

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ: INNL). Investors, who purchased or otherwise acquired Innocoll shares between November 3, 2016 through December 29, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of Innocoll during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

XARACOLL is Innocoll’s lead product candidate. Innocoll issued a New Drug Application (“NDA”) under the U.S. Food & Drug Administration (“FDA”) in October 2016. On December 29, 2016, Innocoll announced that it had received a Refusal to File letter from the FDA as to XARACOLL’s NDA. According to Innocoll, the FDA stated that XARACOLL should be considered a drug/device combination and asked Innocoll to submit further information.

When this information was released to the public, the value of Innocoll stock fell up to 66%, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453846

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against PixarBio Corporation (“PixarBio” or the “Company”) (OTC PINK: PXRB). Investors, who purchased or otherwise acquired PixarBio shares between October 31, 2016, and January 20, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of PixarBio Corporation during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On January 23, 2017, the SEC disclosed the indefinite suspension of trading in the securities of PixarBio “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.” When this information was announced to the public, the value of PixarBio fell, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453841

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, the Company announced that the U.S. Food and Drug Administration had enforced a clinical hold or partial clinical hold on initial stage trials of the Company’s experimental cancer drug, vadastuximab talirine, to assess any possible risk of hepatotoxicity. The Company mentioned that six acute myeloid leukemia patients had been identified with liver toxicity, and that four had died.

When this news was released to the public, the value of Seattle Genetics dropped, causing investors serious harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 453839

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against BT Group plc (“BT Group” or the “Company”) (NYSE: BT) concerning possible violations of federal securities laws between May 23, 2013 and January 23, 2017 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On January 24, 2017, BT Group disclosed a profit warning and suggested that it was lowering its guidance for 2017 and 2018, due to an investigation into the accounting practices at its Italian company.

When this information was released to the public, the value of BT Group stock fell severely, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 453840

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Fenix Parts, Inc. (“Fenix” or the “Company”) (Nasdaq: FENX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Fenix shares between May 14, 2015 and October 12, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 13, 2017 lead plaintiff motion deadline.

If you purchased shares of Fenix during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, during the Class Period, Fenix issued false and/or misleading statements and/or failed to disclose: that its inventory valuation tools were inadequate; that its tools to calculate goodwill impairment were poor; that it was engaging and/or had engaged in activity that would lead to an SEC investigation; and that as a result, Fenix’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

When this information was released to the public, the value of Fenix stock fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453837